Catalent explores clinical supply best practices
The executive summary covers navigating regulatory roadblocks, reducing supply risk, and future-proofing comparator sourcing through integrated models.
See the latest news and media coverage for Catalent. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global contract development and manufacturing organization
catalent.comLast updated
In short: Catalent was acquired by Novo Holdings in a $16.5bn deal amid regulatory backlash and mixed financial results.
The executive summary covers navigating regulatory roadblocks, reducing supply risk, and future-proofing comparator sourcing through integrated models.
The enterprise AI solution helps quality experts investigate manufacturing deviations faster and more consistently across nearly 40 sites.
The transaction secures new credit facilities, lowers borrowing costs by $100 million annually, and improves liquidity for future growth.
The CDMO will serve as primary manufacturer at its Maryland facility under a long-term supply agreement following potential FDA approval.
Catalent stock enters a new financing phase after a USD 4.7 billion refinancing announced on September 1, 2026. The package supports biologics capacity.
Inside Information Agreement provides long-term expanded access to Catalent's fast-dissolving (Zydis®) tablet formulation technology.Supply robustness secured with prioritised manufacturing capacity increase of ~40% to 1.
The American contract manufacturer Catalent plans to continue in exactly that role, also after Novo Holding takes over the company and, according to plan, resells three production facilities to...
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited...
Track Catalent and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Catalent and other trending companies.